Results 91 to 100 of about 4,829 (180)
Waldenström macroglobulinemia is an indolent B-cell lymphoma which although remains incurable, there are a lot of treatment options. Today, Bruton tyrosine kinase inhibitors have a central role in the management of the disease either as monotherapy or ...
Eirini Solia, Efstathios Kastritis
doaj +1 more source
Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy
British Journal of Haematology, Volume 209, Issue 5, Page 2302-2306, November 2026.
Isacco Ferrarini +19 more
wiley +1 more source
B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292
Jon E Arnason,1 Jennifer R Brown21Beth Israel Deaconess Medical Center, 2CLL Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USAAbstract: Chronic lymphocytic leukemia (CLL) is the most common ...
Arnason JE, Brown JR
doaj
Bruton Tyrosine Kinase Inhibitors in Immune-Mediated Skin Diseases: Current Evidence and Future Directions. [PDF]
Wang Z +8 more
europepmc +1 more source
Bruton tyrosine kinase inhibitors for multiple sclerosis. [PDF]
Krämer J +3 more
europepmc +1 more source
Clinical and Translational Science, Volume 19, Issue 11, November 2026.
Paridhi Gupta +3 more
wiley +1 more source
Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia: A Single-Center Retrospective Analysis. [PDF]
Singh M +20 more
europepmc +1 more source

